Meet
Haley Payne

She/Her
Consultant II

Haley Payne provides subject matter expertise in vaccines, preventive services, pandemic preparedness and response, and healthcare quality to support clients' above-brand and brand-level policy objectives.

She leverages experience in stakeholder engagement, advocacy, and state and federal health policy to help clients understand how they may engage with an evolving policy landscape, take advantage of opportunities, and anticipate potential barriers.

Prior to joining Avalere, Haley was the public health policy manager at the Infectious Diseases Society of America (IDSA), where she implemented the society’s policy activities around COVID-19, including vaccine authorization and distribution, and coordinated policy activities to combat antibiotic resistance and emerging infectious diseases. Previously, she served as a legislative associate at the Health and Medicine Counsel, where she represented a variety of patient and provider organizations on Capitol Hill.

Haley has an MPH from George Washington University and a BA in political science from Indiana University.

Authored Content


Policymakers, professional societies, and advocates support the preservation of USPSTF’s evidence-based recommendations and independence amid reported plans for a sweeping overhaul.

Reported plans to reshape the USPSTF align with recent changes to ACIP and may shape the future of preventive care recommendations and access.

The unwinding of COVID-era Medicaid continuous enrollment policies resulted in insurance coverage losses and challenged vaccine access for adults.

This paper presents several proposed changes to the MA Stars Rating program and offers insight into how each proposal would impact federal entities, payers, and members.

Reports that all new vaccines could require placebo-controlled testing are raising stakeholder concerns about the future of vaccine development, approval, and access.

The Vaccine Integrity Project aims to maintain evidence-based US vaccination guidance amidst a dynamic federal policy landscape, although questions remain about the project’s role in the current immunization policy structure.

Avalere Health connected with other public health stakeholders and vaccine experts at World Vaccine Congress to discuss key policy, access, value, and evidence themes.

Policy actions in the first days of the Trump administration raise questions about the future role of key vaccine advisory committees.

In this eBook, Avalere Health Advisory experts discuss the evolving vaccines ecosystem and analyze key policy issues affecting vaccines manufacturers.

Following policy changes addressing vaccine coverage gaps, stakeholders are focusing on provider financial and administrative barriers to vaccination.

The IRA expanded vaccine access, but variations in federal policies governing vaccine coverage requirements and implementation remain

In light of the growing therapeutic vaccine pipeline, policymakers are starting to define coverage, access, and reimbursement pathways.

Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.

Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.

CMS is proposing to update vaccine administration reimbursement rates annually and make changes to adult vaccination quality metrics, beginning in 2023.

The rollout of COVID-19 vaccines highlights the need for continued innovation in how vaccines are delivered.

The COVID-19 pandemic identified gaps in US public health infrastructure and resources, prompting policy proposals and opportunities for stakeholder engagement.

Updated Avalere analysis shows that routine immunization continued to lag in 2021 below pre-pandemic levels, highlighting the continuing effect of COVID-19 on routine vaccination.

The COVID-19 pandemic has brought renewed attention and urgency to mitigating access barriers to recommended vaccines.

The COVID-19 pandemic response has increased investment in vaccine innovations, but also exposed gaps in US and global vaccine access and delivery.

As the COVID-19 pandemic draws to a close in the US, another public health concern is once again coming to the fore: antimicrobial resistance (AMR).